JP6885870B2 - 間葉系幹細胞の細胞培養法 - Google Patents
間葉系幹細胞の細胞培養法 Download PDFInfo
- Publication number
- JP6885870B2 JP6885870B2 JP2017546094A JP2017546094A JP6885870B2 JP 6885870 B2 JP6885870 B2 JP 6885870B2 JP 2017546094 A JP2017546094 A JP 2017546094A JP 2017546094 A JP2017546094 A JP 2017546094A JP 6885870 B2 JP6885870 B2 JP 6885870B2
- Authority
- JP
- Japan
- Prior art keywords
- culture medium
- cell culture
- pdgf
- level
- fgf2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims description 79
- 238000004113 cell culture Methods 0.000 title description 24
- 239000006143 cell culture medium Substances 0.000 claims description 283
- 210000000130 stem cell Anatomy 0.000 claims description 166
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 165
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 165
- 108010081589 Becaplermin Proteins 0.000 claims description 132
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 108
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 104
- 229940116977 epidermal growth factor Drugs 0.000 claims description 104
- 239000002609 medium Substances 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 49
- 230000004663 cell proliferation Effects 0.000 claims description 48
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 43
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 43
- 230000001605 fetal effect Effects 0.000 claims description 25
- 241000283690 Bos taurus Species 0.000 claims description 24
- 239000001963 growth medium Substances 0.000 claims description 17
- 239000007640 basal medium Substances 0.000 claims description 14
- 238000000338 in vitro Methods 0.000 claims description 11
- 230000001737 promoting effect Effects 0.000 claims description 10
- 239000007758 minimum essential medium Substances 0.000 claims description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 4
- 210000004027 cell Anatomy 0.000 description 138
- 102400001368 Epidermal growth factor Human genes 0.000 description 100
- 108010000685 platelet-derived growth factor AB Proteins 0.000 description 85
- 239000000203 mixture Substances 0.000 description 49
- 210000002966 serum Anatomy 0.000 description 25
- 239000003102 growth factor Substances 0.000 description 23
- 230000035755 proliferation Effects 0.000 description 20
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 19
- 229960002897 heparin Drugs 0.000 description 16
- 229920000669 heparin Polymers 0.000 description 16
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 15
- 239000012091 fetal bovine serum Substances 0.000 description 15
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 14
- 238000012258 culturing Methods 0.000 description 14
- 230000012010 growth Effects 0.000 description 14
- 239000003550 marker Substances 0.000 description 14
- 230000006698 induction Effects 0.000 description 13
- 150000000996 L-ascorbic acids Chemical class 0.000 description 12
- 102100025683 Alkaline phosphatase, tissue-nonspecific isozyme Human genes 0.000 description 11
- JLTPSDHKZGWXTD-UHFFFAOYSA-N 2-[6-(dicyanomethylidene)naphthalen-2-ylidene]propanedinitrile Chemical compound N#CC(C#N)=C1C=CC2=CC(=C(C#N)C#N)C=CC2=C1 JLTPSDHKZGWXTD-UHFFFAOYSA-N 0.000 description 10
- 101710161969 Alkaline phosphatase, tissue-nonspecific isozyme Proteins 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000006166 lysate Substances 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 9
- 210000000988 bone and bone Anatomy 0.000 description 8
- 210000001185 bone marrow Anatomy 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000012986 modification Methods 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 210000001778 pluripotent stem cell Anatomy 0.000 description 6
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 5
- 230000000735 allogeneic effect Effects 0.000 description 5
- 239000003797 essential amino acid Substances 0.000 description 5
- 235000020776 essential amino acid Nutrition 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000003226 mitogen Substances 0.000 description 4
- 210000004498 neuroglial cell Anatomy 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 3
- 102100037362 Fibronectin Human genes 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 101150052863 THY1 gene Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- 210000004700 fetal blood Anatomy 0.000 description 3
- 229940126864 fibroblast growth factor Drugs 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229910021653 sulphate ion Inorganic materials 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 102100034594 Angiopoietin-1 Human genes 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 2
- 229920002971 Heparan sulfate Polymers 0.000 description 2
- 101000924552 Homo sapiens Angiopoietin-1 Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 108091008606 PDGF receptors Proteins 0.000 description 2
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 230000003021 clonogenic effect Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000012606 in vitro cell culture Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 210000003668 pericyte Anatomy 0.000 description 2
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000004500 stellate cell Anatomy 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 102000006573 Chemokine CXCL12 Human genes 0.000 description 1
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000160765 Erebia ligea Species 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000574445 Homo sapiens Alkaline phosphatase, tissue-nonspecific isozyme Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 1
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 description 1
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- 239000012534 cell culture medium component Substances 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 210000001968 dental pulp cell Anatomy 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 210000001755 duct epithelial cell Anatomy 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 210000000442 hair follicle cell Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 239000002628 heparin derivative Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000010859 live-cell imaging Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000004786 perivascular cell Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000035409 positive regulation of cell proliferation Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- -1 tetrahexyldecyl Chemical group 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/99—Serum-free medium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/135—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/115—Platelets, megakaryocytes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021042409A JP7410899B2 (ja) | 2015-03-04 | 2021-03-16 | 間葉系幹細胞の細胞培養法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015900752 | 2015-03-04 | ||
| AU2015900752A AU2015900752A0 (en) | 2015-03-04 | Cell culture method | |
| AU2015900777 | 2015-03-05 | ||
| AU2015900777A AU2015900777A0 (en) | 2015-03-05 | Cell culture method | |
| PCT/EP2016/054640 WO2016139340A1 (en) | 2015-03-04 | 2016-03-04 | Cell culture method for mesenchymal stem cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021042409A Division JP7410899B2 (ja) | 2015-03-04 | 2021-03-16 | 間葉系幹細胞の細胞培養法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018506986A JP2018506986A (ja) | 2018-03-15 |
| JP2018506986A5 JP2018506986A5 (OSRAM) | 2019-04-11 |
| JP6885870B2 true JP6885870B2 (ja) | 2021-06-16 |
Family
ID=55453191
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546094A Active JP6885870B2 (ja) | 2015-03-04 | 2016-03-04 | 間葉系幹細胞の細胞培養法 |
| JP2021042409A Active JP7410899B2 (ja) | 2015-03-04 | 2021-03-16 | 間葉系幹細胞の細胞培養法 |
| JP2023173585A Pending JP2024001179A (ja) | 2015-03-04 | 2023-10-05 | 間葉系幹細胞の細胞培養法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021042409A Active JP7410899B2 (ja) | 2015-03-04 | 2021-03-16 | 間葉系幹細胞の細胞培養法 |
| JP2023173585A Pending JP2024001179A (ja) | 2015-03-04 | 2023-10-05 | 間葉系幹細胞の細胞培養法 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US20180037867A1 (OSRAM) |
| EP (2) | EP4008775A1 (OSRAM) |
| JP (3) | JP6885870B2 (OSRAM) |
| KR (1) | KR102635212B1 (OSRAM) |
| CN (2) | CN107567494A (OSRAM) |
| AU (2) | AU2016227607B2 (OSRAM) |
| BR (1) | BR112017018885A2 (OSRAM) |
| CA (1) | CA2977578C (OSRAM) |
| SG (1) | SG11201706886PA (OSRAM) |
| WO (1) | WO2016139340A1 (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3095856T3 (da) | 2008-09-16 | 2019-10-21 | Mayo Found Medical Education & Res | Sammensætninger med trombocytindhold |
| WO2012048099A2 (en) | 2010-10-08 | 2012-04-12 | Osiris Therapeutics, Inc. | Nanoparticle-loaded cells |
| CA3138143A1 (en) | 2014-05-16 | 2015-11-19 | Mayo Foundation For Medical Education And Research | Cell culture media compositions for primary cells |
| EP4008775A1 (en) | 2015-03-04 | 2022-06-08 | Mesoblast International Sàrl | Cell culture method for mesenchymal stem cells |
| EP3714038A1 (en) | 2017-11-22 | 2020-09-30 | Mesoblast International Sàrl | Cellular compositions and methods of treatment i |
| CN108251358B (zh) * | 2017-12-15 | 2021-10-26 | 广东药科大学 | 一种相同供体来源人间充质干细胞的多批次原代分离方法 |
| US20210115395A1 (en) * | 2018-03-28 | 2021-04-22 | Pluristem Ltd. | Methods for expanding adherent stromal cells and cells obtained thereby |
| CN108624554B (zh) * | 2018-05-14 | 2021-09-14 | 山东大学 | 一种非基因修饰光操控双向调节人脐带间充质干细胞增殖的方法 |
| WO2020060809A1 (en) * | 2018-09-17 | 2020-03-26 | Rejuvablast LLC | Combination grafts for tissue repair or regeneration applications |
| WO2020067443A1 (ja) * | 2018-09-27 | 2020-04-02 | テルモ株式会社 | 体細胞のシート化方法 |
| CN115997005A (zh) * | 2020-06-11 | 2023-04-21 | 迈索布拉斯特国际有限公司 | 间充质谱系前体或干细胞的3d培养 |
| CN117529234A (zh) * | 2021-03-10 | 2024-02-06 | 寺崎生物医学创新研究所 | 生产产品例如动物源性产品的方法和系统 |
| EP4304383A4 (en) * | 2021-03-10 | 2025-02-26 | Terasaki Institute For Biomedical Innovation | GROWTH FACTORS FOR LABORATORY-GROWN MEAT AND OTHER APPLICATIONS |
| WO2024121818A1 (en) | 2022-12-09 | 2024-06-13 | Mesoblast International Sarl | Method of treating heart failure in subjects with persistent inflammation |
| CN120641115A (zh) | 2022-12-09 | 2025-09-12 | 迈索布拉斯特国际有限公司 | 用细胞组合物治疗炎症的方法 |
| KR20250134601A (ko) | 2022-12-09 | 2025-09-11 | 메조블라스트 인터내셔널 에스에이알엘 | 조건화 배지 및 그 용도 |
| JP2025538783A (ja) | 2022-12-09 | 2025-11-28 | メゾブラスト・インターナショナル・エスアーエールエル | 事前承認された組成物及び細胞培養方法 |
| WO2024225602A1 (ko) * | 2023-04-24 | 2024-10-31 | 파미셀 주식회사 | 뉴클레오시드 함유 세포 배양배지 및 이를 이용한 세포 배양 방법 |
| WO2025046491A1 (en) | 2023-08-28 | 2025-03-06 | Mesoblast International Sàrl | Third line treatment for gvhd |
| WO2025062365A1 (en) | 2023-09-22 | 2025-03-27 | Mesoblast International Sárl | Mesenchymal lineage precursor or stem cells (mlpscs) for use in methods of treating congenital heart disease |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5486359A (en) | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
| EP0978259B1 (de) | 1991-08-12 | 2002-02-20 | Karl Storz GmbH & Co. KG | Hochfrequenzchirurgiegenerator mit einer einstellbaren Ausgangsleistung |
| US5814464A (en) | 1994-10-07 | 1998-09-29 | Regeneron Pharma | Nucleic acids encoding TIE-2 ligand-2 |
| US6277372B1 (en) | 1994-11-08 | 2001-08-21 | Diacrin, Inc. | Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases |
| US6204053B1 (en) | 1994-11-08 | 2001-03-20 | Diacrin, Inc. | Porcine cortical cells and their use in treatment of neurological deficits due to neurodegenerative diseases |
| ATE273384T1 (de) | 1995-04-06 | 2004-08-15 | Regeneron Pharma | Tie-2 liganden, herstellungsverfahren und verwendung |
| AU5734998A (en) | 1997-01-10 | 1998-08-03 | Life Technologies, Inc. | Embryonic stem cell serum replacement |
| US5968829A (en) | 1997-09-05 | 1999-10-19 | Cytotherapeutics, Inc. | Human CNS neural stem cells |
| RU2272839C2 (ru) * | 1998-11-09 | 2006-03-27 | Консорцио Пер Ла Джестионе Дель Чентро Ди Биотекнолоджие Аванцате | Бессывороточная среда для культуры клеток, используемых для реконструкции костных и хрящевых сегментов (варианты) |
| AU2003901668A0 (en) | 2003-03-28 | 2003-05-01 | Medvet Science Pty. Ltd. | Non-haemopoietic precursor cells |
| WO2001028574A2 (en) | 1999-10-20 | 2001-04-26 | Stem Cells, Inc. | Methods for inducing in vivo proliferation and migration of transplanted progenitor cells in the brain |
| US7439064B2 (en) * | 2000-03-09 | 2008-10-21 | Wicell Research Institute, Inc. | Cultivation of human embryonic stem cells in the absence of feeder cells or without conditioned medium |
| JP2004528021A (ja) | 2001-02-14 | 2004-09-16 | アンスロジェネシス コーポレーション | 分娩後の哺乳動物の胎盤、その使用およびそれに由来する胎盤幹細胞 |
| ES2545899T3 (es) | 2001-02-14 | 2015-09-16 | Anthrogenesis Corporation | Placenta post-parto de mamíferos, su uso y células madre placentarias de la misma |
| JP2005500847A (ja) | 2001-08-24 | 2005-01-13 | アドバンスド セル テクノロジー、インコーポレイテッド | 分化誘導薬の同定のためのスクリーニング検定及び細胞治療用の分化細胞の調製 |
| MXPA04007732A (es) | 2002-02-13 | 2004-10-15 | Anthrogenesis Corp | Celulas madre similares a las embrionarias, derivadas de la placenta de mamiferos despues del parto y usos y metodos de tratamiento usando dichas celulas. |
| WO2003102134A2 (en) | 2002-05-28 | 2003-12-11 | Becton, Dickinson And Company | Pancreatic acinar cells into insulin producing cells |
| EP1507552A2 (en) | 2002-05-28 | 2005-02-23 | Novocell, Inc. | Methods, compositions, and growth and differentiation factors for insulin-producing cells |
| EP1641915B1 (en) | 2003-06-27 | 2016-07-27 | DePuy Synthes Products, Inc. | Repair and regeneration of ocular tissue using postpartum-derived cells |
| US8491883B2 (en) | 2003-06-27 | 2013-07-23 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of amyotrophic lateral sclerosis using umbilical derived cells |
| EP1758984A2 (en) | 2004-02-26 | 2007-03-07 | Reliance Life Sciences Pvt., Ltd. | Pluripotent embryonic-like stem cells derived from corneal limbus, methods of isolation and uses thereof |
| ES2621847T3 (es) | 2004-12-23 | 2017-07-05 | DePuy Synthes Products, Inc. | Células posparto derivadas de tejido de cordón umbilical, y métodos de elaboración y uso de las mismas |
| EP1833496B1 (en) | 2004-12-23 | 2013-07-31 | Ethicon, Incorporated | Treatment of stroke and other acute neural degenerative disorders using postpartum derived cells |
| WO2006071773A2 (en) | 2004-12-23 | 2006-07-06 | Ethicon Incoporated | Treatment of osteochondral diseases using postpartum-derived cells and products thereof |
| WO2006071777A2 (en) | 2004-12-23 | 2006-07-06 | Ethicon Incorporated | Soft tissue repair and regeneration using postpartum-derived cells and cell products |
| US20080199849A1 (en) | 2005-09-02 | 2008-08-21 | Agency For Science, Technology And Research | Method of Deriving Progenitor Cell Line |
| KR101107835B1 (ko) | 2006-01-13 | 2012-02-09 | 가부시키가이샤 투셀 | 동물 세포의 무혈청 배양에 사용하기 위한 배양 배지 첨가물, 키트 및 이의 용도 |
| US20090232777A1 (en) * | 2006-03-01 | 2009-09-17 | Evy Lundgren-Akerlund | Expansion and Differentiation of Mesenchymal Stem Cells |
| JP2010500047A (ja) * | 2006-08-15 | 2010-01-07 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | 間葉系幹細胞馴化培地 |
| JP2008148643A (ja) * | 2006-12-19 | 2008-07-03 | Olympus Corp | 無血清培地および幹細胞の培養方法 |
| RS52921B (sr) | 2007-02-12 | 2014-02-28 | Anthrogenesis Corporation | Lečenje inflamatornih bolesti upotrebom placentnih matičnih ćelija |
| WO2008151390A1 (en) | 2007-06-15 | 2008-12-18 | Australian Stem Cell Centre Ltd | Differentiation of human embryonic stem cells |
| US20110236971A2 (en) * | 2007-09-25 | 2011-09-29 | Maksym Vodyanyk | Generation of Clonal Mesenchymal Progenitors and Mesenchymal Stem Cell Lines Under Serum-Free Conditions |
| KR101224588B1 (ko) * | 2008-01-24 | 2013-01-22 | 삼성전자주식회사 | 멀티포인트 스트록을 감지하기 위한 ｕｉ 제공방법 및 이를적용한 멀티미디어 기기 |
| US20110110888A1 (en) | 2008-06-27 | 2011-05-12 | Hai-Qing Xian | Scaffold Coated and/or Impregnated with at Least One Bioactive Agent for Tissue Repair and Other Medical Applications |
| US20100055078A1 (en) * | 2008-08-15 | 2010-03-04 | The Government of the U.S.A, as represented by the Department of Veterans Affairs | Methods of making a transplantable bone repair system using multipotent stem cells |
| US20110212523A1 (en) | 2008-11-11 | 2011-09-01 | Yukio Kato | Differentiation-inducing culture medium additive and use thereof |
| US20100158878A1 (en) | 2008-12-23 | 2010-06-24 | Alexandra Capela | Target populations of oligodendrocyte precursor cells and methods of making and using same |
| US10894944B2 (en) | 2009-04-10 | 2021-01-19 | Monash University | Cell culture media |
| US9394521B2 (en) * | 2010-03-10 | 2016-07-19 | Two Cells Co., Ltd. | Cell preparation containing mesenchymal stem cells, and method for producing same |
| AU2011265723A1 (en) * | 2010-06-17 | 2013-01-10 | Stemrd, Inc. | Serum-free chemically defined cell culture medium |
| CA2821065C (en) * | 2011-01-12 | 2021-05-18 | Tsuneo KIDO | Culture method to obtain and maintain a pure or enriched population of mammalian neural stem cells and/or neural progenitor cells that are prone to differentiate into oligodendrocyte-lineage cells in vitro |
| KR101523040B1 (ko) * | 2012-06-26 | 2015-05-26 | 라정찬 | 고농도의 줄기세포 제조방법 |
| WO2014082685A1 (en) * | 2012-11-30 | 2014-06-05 | Swiss Stem Cell Foundation | Serum-free medium for human mesenchymal stem cells |
| CN103396984B (zh) * | 2013-07-25 | 2016-02-10 | 宗兆文 | 一种利用皮肤来源的祖细胞制备组织工程脊髓的方法 |
| EP4008775A1 (en) | 2015-03-04 | 2022-06-08 | Mesoblast International Sàrl | Cell culture method for mesenchymal stem cells |
-
2016
- 2016-03-04 EP EP21205011.6A patent/EP4008775A1/en active Pending
- 2016-03-04 KR KR1020177025840A patent/KR102635212B1/ko active Active
- 2016-03-04 EP EP16707810.4A patent/EP3265554B1/en active Active
- 2016-03-04 SG SG11201706886PA patent/SG11201706886PA/en unknown
- 2016-03-04 CA CA2977578A patent/CA2977578C/en active Active
- 2016-03-04 CN CN201680025469.8A patent/CN107567494A/zh active Pending
- 2016-03-04 US US15/553,115 patent/US20180037867A1/en not_active Abandoned
- 2016-03-04 JP JP2017546094A patent/JP6885870B2/ja active Active
- 2016-03-04 CN CN202111251410.XA patent/CN113957043A/zh active Pending
- 2016-03-04 BR BR112017018885A patent/BR112017018885A2/pt not_active Application Discontinuation
- 2016-03-04 AU AU2016227607A patent/AU2016227607B2/en active Active
- 2016-03-04 WO PCT/EP2016/054640 patent/WO2016139340A1/en not_active Ceased
-
2019
- 2019-10-11 US US16/599,271 patent/US11685899B2/en active Active
-
2021
- 2021-03-16 JP JP2021042409A patent/JP7410899B2/ja active Active
- 2021-10-19 AU AU2021254538A patent/AU2021254538B2/en active Active
-
2023
- 2023-03-21 US US18/124,346 patent/US12215352B2/en active Active
- 2023-10-05 JP JP2023173585A patent/JP2024001179A/ja active Pending
-
2024
- 2024-12-24 US US19/001,125 patent/US20250129337A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016139340A1 (en) | 2016-09-09 |
| US11685899B2 (en) | 2023-06-27 |
| US20200040303A1 (en) | 2020-02-06 |
| US20180037867A1 (en) | 2018-02-08 |
| EP3265554A1 (en) | 2018-01-10 |
| SG11201706886PA (en) | 2017-09-28 |
| JP7410899B2 (ja) | 2024-01-10 |
| AU2016227607A1 (en) | 2017-09-07 |
| US20250129337A1 (en) | 2025-04-24 |
| JP2021090463A (ja) | 2021-06-17 |
| AU2021254538B2 (en) | 2024-01-18 |
| EP4008775A1 (en) | 2022-06-08 |
| US20240191200A1 (en) | 2024-06-13 |
| CN113957043A (zh) | 2022-01-21 |
| CA2977578A1 (en) | 2016-09-09 |
| CA2977578C (en) | 2024-09-10 |
| AU2021254538A1 (en) | 2021-11-18 |
| JP2018506986A (ja) | 2018-03-15 |
| US12215352B2 (en) | 2025-02-04 |
| EP3265554B1 (en) | 2021-11-17 |
| KR102635212B1 (ko) | 2024-02-13 |
| KR20170120627A (ko) | 2017-10-31 |
| JP2024001179A (ja) | 2024-01-09 |
| BR112017018885A2 (pt) | 2018-04-17 |
| AU2016227607B2 (en) | 2021-09-30 |
| CN107567494A (zh) | 2018-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7410899B2 (ja) | 間葉系幹細胞の細胞培養法 | |
| JP7571109B2 (ja) | 改善された幹細胞組成物 | |
| Braun et al. | Evaluation of the osteogenic and chondrogenic differentiation capacities of equine adipose tissue-derived mesenchymal stem cells | |
| Alonso-Goulart et al. | Mesenchymal stem cells from human adipose tissue and bone repair: a literature review | |
| BR112014020119A2 (pt) | cultura de células-tronco mesenquimais | |
| JP2017506511A (ja) | 無血清培地 | |
| Harkness et al. | Selective isolation and differentiation of a stromal population of human embryonic stem cells with osteogenic potential | |
| HUANG et al. | Characterization and differentiation into adipocytes and myocytes of porcine bone marrow mesenchymal stem cells | |
| US20080113434A1 (en) | Serum-Free Suspension Culture System For Mesenchymal Progenitor Cells | |
| Varga et al. | Mesenchymal stem cell like (MSCl) cells generated from human embryonic stem cells support pluripotent cell growth | |
| JP2025538784A (ja) | 馴化培地及びその使用 | |
| HK40074091A (en) | Cell culture method for mesenchymal stem cells | |
| Lauvrud et al. | The influence of xeno-free culture conditions on the angiogenic and adipogenic differentiation properties of adipose tissue-derived stem cells | |
| HK1240971B (en) | Cell culture method for mesenchymal stem cells | |
| BR122024005049A2 (pt) | Método de cultura celular para células-tronco mesenquimais | |
| Joshi | Master of Veterinary | |
| Gaynard | In vitro, pre-clinical and commercial evaluation of a novel xeno-and serum-free culture system for production of human bone marrow derived mesenchymal stem cells for bone regeneration | |
| Ferro | Isolation, characterization and Ex-Vivo expansion of human synovial tissue derived-mesenchymal stem/stromal cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190301 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190301 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20191219 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200120 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200420 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200611 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20201116 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210316 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20210316 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20210323 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20210329 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210419 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210513 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6885870 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |